Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You have a link? I don’t use Twitter
Thnx
GTHP break 4’s and she’s running
Give it some time, it just might
GTHP
Bid building at 3 here
Let MAXM finish today
GTHP 3’s gone
GTHP 3’s gone
HEAVY VOLUME
$GTHP .0003 Huge News out!! Central/Eastern European/Russian Distributor Expands LuViva Program by Signing Manufacturing, Supply and Royalty Agreement; Projects Purchases of $30 Million over 5 Years Business Wire "Press Releases - English"
NORCROSS, Ga. --(BUSINESS WIRE)-- Guided Therapeutics, Inc. (PINK SHEETS: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced that it has signed a limited Manufacturing, Supply and Royalty Agreement with its Central/Eastern European/Russian distribution partner Newmars Technologies, Inc.
The agreement enables Newmars to manufacture LuViva Advance Cervical Scan devices in Hungary for distribution in the nine Central and Eastern European countries for which Newmars has distribution rights. GTHP will manufacture sub-assemblies and sell these and other parts to Newmars and will receive an additional $2,000 royalty for each device sold in those countries, which include Russia , Ukraine , Poland , Romania , Hungary , Moldova , Kazakhstan , Belarus and Armenia .
Guided Therapeutics will continue to sell single use, disposable Cervical Guides to Newmars and they are not part of the new agreement. Newmars projects sales of over 700 LuViva devices and over 1.5 million Cervical Guides. Combined with the previously signed distribution agreement, this new agreement is expected to generate approximately $30 million in revenues for GTHP over the next 5 years, with sales beginning in the second half of next year.
We are encouraged by the work that Newmars has done so far in both Russia and Hungary and we are confident that there is a substantial market in Eastern Europe for LuViva, said Gene Cartwright , CEO of Guided Therapeutics .
The population of the nine countries is nearly 300 million and the number of women of recommended cervical cancer screening age is over 70 million for these 9 countries.
About Guided Therapeutics
Guided Therapeutics, Inc. (PINK SHEETS: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Companys first product is the LuViva Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com.
The Guided Therapeutics LuViva Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.
Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading Risk Factors in Guided Therapeutics reports filed with the SEC , including Guided Therapeutics Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and subsequent filings.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181218005514/en/
Mark Faupel Guided Therapeutics 770-242-8723
Source: Guided Therapeutics, Inc.
Report TOS
Hopefully they finish converting here with this heavy volume on news
GTHP
Crazy volume
Let’s go GTHP
207 share trade at .0003 worth .06 to paint it down
He was totally gone when 4’s were up
Watch and you will see
GTHP
MAXM completely off the ask side
GTHP
GTHP chart getting ready to pop up hard
OS #’s Updated
11/27 — 809,983,322
11/28 — 842,661,289
11/29 — 879,213,013
12/03 — 952,284,852
12/05 — 1,057,696,014
12/06 — 1,187,758,835
12/10 — 1,220,793,318
12/11 — 1,273,572,318
12/12 — 1,273,572,318
12/13 — 1,329,107,747
Bid building
GTHP
GTHP found bottom, dilution seems to be over
Clean and thin L2
Front loaders, dumpers and dilution seem to be all gone
L2 looks clean and thin
Now is the time to drop news of NO RS
GTHP
No idea, wish I had the answer for you but I don’t.
GTHP
Dilution looking like it’s coming to a end here
GTHP
OS #’s Updated
11/27 — 809,983,322
11/28 — 842,661,289
11/29 — 879,213,013
12/03 — 952,284,852
12/05 — 1,057,696,014
12/06 — 1,187,758,835
12/10 — 1,220,793,318
12/11 — 1,273,572,318
12/12 — 1,273,572,318
Don’t bother with him or her..notice how this person won’t reply to your message directly but still will answer it with a post
That’s if they need to do it
And that’s if the SEC or FINRA allows it to pass!!
So go back to sleep
GTHP
L2 looks clean and thin
GTHP
OS #’s Updated
11/27 — 809,983,322
11/28 — 842,661,289
11/29 — 879,213,013
12/03 — 952,284,852
12/05 — 1,057,696,014
12/06 — 1,187,758,835
12/10 — 1,220,793,318
12/11 — 1,273,572,318
Maxm has been pinned at 8.00 all day didn’t even come out to play
GTHP
4’s about to go again. Let’s hope that’s the last of em
GTHP
GTHP .0005’s up and hit
GTHP 5’s up and hit
Forget about this clown guy
GTHP 10 milly hit on .0004
GTHP nice 10 million hit on the ask
Definitely looks like it. Let’s hope they drop some atomic type of awesome news to get this back where it should be..
GTHP
OS #’s Updated
11/27 — 809,983,322
11/28 — 842,661,289
11/29 — 879,213,013
12/03 — 952,284,852
12/05 — 1,057,696,014
12/06 — 1,187,758,835
12/10 — 1,220,793,318
Looks like dilution has stopped for now
Totally up to GTHP to get this going here
Dude you flip flop every other day over here. You make 0 sense
3 Billion is a joke in Otc pinky land
Look at CBDD they got 4 billion
Let them say RS off the table and this thing will fly..
GTHP
Only MM can trade five digit trades
Not enough volume for them to dilute so let’s see what happens
GTHP
GTHP .0003’s bottom?? Hopefully
They definitely gotta be running low on shares soon
GTHP good times ahead of these growing pains
OS #’s Updated
11/27 — 809,983,322
11/28 — 842,661,289
11/29 — 879,213,013
12/03 — 952,284,852
12/05 — 1,057,696,014
12/06 — 1,187,758,835